Morning Overview on MSN
China turns a buried $50M tunnel failure into a precision-engineering win
Deep under the Yangtze River, a stranded tunnel boring machine that looked like a sunk cost has instead become a showcase of ...
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...
Since its US, Japan, and China approvals, the ROS1-positive NSCLC drug recorded $15.7 million and $24.7 million in revenue in Q4 and full-year 2025, respectively.
The company will use the funds to advance its drug design platform and lead program in EGFR-expressing solid tumors and expand globally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback